Umbilical Cord Mesenchymal Stromal Cell with Autologous Bone Marrow Cell Transplantation in Established Type 1 Diabetes: A Pilot Randomized Controlled Open-Label Clinical Study to Assess Safety and Impact on Insulin Secretion

Diabetes Care

Volumn 39, Issue 1, 2016, Pages 149-157

  Cai, Jinquan ^a   Wu, Zhixian ^a   Xu, Xiumin ^b,c,d,e   Liao, Lianming ^a   Chen, Jin ^a   Huang, Lianghu ^a   Wu, Weizhen ^a   Luo, Fang ^a   Wu, Chenguang ^a   Pugliese, Alberto ^b,e   Pileggi, Antonello ^b,c,d,e   Ricordi, Camillo ^b,c,d,e   Tan, Jianming ^a,c,d  

^a XIAMEN UNIVERSITY   (China)

^b UNIVERSITY OF MIAMI   (United States)

^c Diabetes Research Institute Federation   (United States)

^d Cure Alliance ^*  (United States)

^e UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; C PEPTIDE; GAMMA INTERFERON; GLUCOSE; HEMOGLOBIN A1C; INTERLEUKIN 10; INSULIN;

ABDOMINAL PAIN; ADULT; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; METABOLIC REGULATION; ORAL GLUCOSE TOLERANCE TEST; PATIENT SAFETY; PILOT STUDY; POSTOPERATIVE HEMORRHAGE; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; ADOLESCENT; AUTOTRANSPLANTATION; BLOOD; BONE MARROW TRANSPLANTATION; CHILD; CYTOLOGY; DIABETES MELLITUS, TYPE 1; GLUCOSE TOLERANCE TEST; PRESCHOOL CHILD; SECRETION (PROCESS); UMBILICAL CORD; YOUNG ADULT;

ADOLESCENT; ADULT; BONE MARROW TRANSPLANTATION; C-PEPTIDE; CHILD; CHILD, PRESCHOOL; DIABETES MELLITUS, TYPE 1; FEMALE; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; PILOT PROJECTS; QUALITY OF LIFE; TRANSPLANTATION, AUTOLOGOUS; UMBILICAL CORD; YOUNG ADULT;

EID: 84962092490     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc15-0171     Document Type: Article

References (40)

1. Pugliese A. The multiple origins of type 1 diabetes. Diabet Med 2012;30:135-146
2. Skyler JS, Ricordi C. Stopping type 1 diabetes: Attempts to prevent or cure type 1 diabetes in man. Diabetes 2011;60:1-8
3. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulindependent diabetes mellitus. N Engl J Med 1993; 329:977-986
4. Zgibor JC, Songer TJ, Kelsey SF, et al. The association of diabetes specialist care with health care practices and glycemic control in patients with type 1 diabetes: A cross-sectional analysis from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Care 2000;23:472-476
5. Beilhack GF, Scheffold YC, Weissman IL, et al. Purified allogeneic hematopoietic stem cell transplantation blocks diabetes pathogenesis in NOD mice. Diabetes 2003;52:59-68
6. Couri CE, De Oliveira MC, Simões BP. Risks, benefits, and therapeutic potential of hematopoietic stem cell transplantation for autoimmune diabetes. Curr Diab Rep 2012;12:604-611
7. Voltarelli JC, Couri CE, Stracieri AB, et al. Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA 2007;297:1568-1576
8. Li L, Shen S, Ouyang J, et al. Autologous hematopoietic stemcell transplantationmodulates immunocompetent cells and improves b-cell function in Chinese patients with new onset of type 1 diabetes. J Clin Endocrinol Metab 2012; 97:1729-1736
9. Carlsson PO, Schwarcz E, Korsgren O, Le Blanc K. Preserved b-cell function in type 1 diabetes by mesenchymal stromal cells. Diabetes 2015;64:587-592
10. D'Addio F, Valderrama Vasquez A, BenNasr M, et al. Autologous nonmyeloablative hematopoietic stem cell transplantation in new-onset type 1 diabetes: A multicenter analysis. Diabetes 2014;63: 3041-3046
11. Wang J, Liao L, Tan J. Mesenchymal-stemcell-based experimental and clinical trials: Current status and open questions. Expert Opin Biol Ther 2011;11:893-909
12. Urbán VS, Kiss J, Kovács J, et al.Mesenchymal stem cells cooperate with bone marrow cells in therapy of diabetes. Stem Cells 2008;26:244-253
13. Thakkar UG, Trivedi HL, Vanikar AV, Dave SD. Insulin-secreting adipose-derived mesenchymal stromal cells with bone marrow-derived hematopoietic stem cells from autologous and allogenic sources for type 1 diabetes mellitus. Cytotherapy 2015;17:940-947
14. Rowe PA, Campbell-Thompson ML, Schatz DA, Atkinson MA. The pancreas in human type 1 diabetes. Semin Immunopathol 2011;33:29-43
15. Wang L, Lovejoy NF, Faustman DL. Persistence of prolonged C-peptide production in type 1 diabetes as measured with an ultrasensitive C-peptide assay. Diabetes Care 2012;35:465-470
16. Oram RA, Jones AG, Besser RE, et al. The majority of patients with long-duration type 1 diabetes are insulin microsecretors and have functioning beta cells. Diabetologia 2014;57:187-191
17. Huang YY, Huang P, Lou HL. Value of glutamic acid decarboxylase autoantibody detection for early diagnosis of latent autoimmune diabetes in adults. Di Yi Jun Yi Da Xue Xue Bao 2003; 23:868-869 [in Chinese]
18. Tan J, Qiu J, Tang X. HLA amino acid residue matching in 2575 kidney transplants. Transplant Proc 2007;39:1429-1431
19. Tan J, Wu W, Xu X, et al. Induction therapy with autologous mesenchymal stem cells in living-related kidney transplants: A randomized controlled trial. JAMA 2012;307:1169-1177
20. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006;8:315-317
21. Wu ZX, Yang XZ, Cai JQ, et al. Digital subtraction angiography and computed tomography angiography of predominant artery feeding pancreatic body and tail. Diabetes Technol Ther 2011;13:537-541
22. Thunander M, Törn C, Petersson C, Ossiansson B, Fornander J, Landin-Olsson M. Levels of C-peptide, body mass index and age, and their usefulness in classification of diabetes in relation to autoimmunity, in adults with newly diagnosed diabetes in Kronoberg, Sweden. Eur J Endocrinol 2012;166:1021-1029
23. Liu CL, Yu YR, Liu H, Zhang XX, Zhao GZ. The associations of HLA-DQB1 gene with onset age and autoantibodies in type 1 diabetes. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2004;21: 368-371 [in Chinese]
24. Zhou H, Wu Z, Ma L, et al. Assessing immunologic function through CD4 T-lymphocyte adenosine triphosphate levels by ImmuKnow assay in Chinese patients following renal transplantation. Transplant Proc 2011;43:2574-2578
25. Gu Y, Zhang M, Chen H, et al. Discordant association of islet autoantibodies with highrisk HLA genes in Chinese type 1 diabetes. Diabetes Metab Res Rev 2011;27:899-905
26. Le Blanc K, Frassoni F, Ball L, et al.; Developmental Committee of the European Group for Blood and Marrow Transplantation. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: A phase II study. Lancet 2008;371:1579-1586
27. Pileggi A, Xu X, Tan J, Ricordi C. Mesenchymal stromal (stem) cells to improve solid organ transplant outcome: Lessons from the initial clinical trials. Curr Opin Organ Transplant 2013;18:672-681
28. Lalu MM, McIntyre L, Pugliese C, et al.; Canadian Critical Care Trials Group. Safety of cell therapy with mesenchymal stromal cells (SafeCell): A systematic review and meta-analysis of clinical trials. PLoS One 2012;7:e47559
29. Hu J, Yu X, Wang Z, et al. Long term effects of the implantation of Wharton's jelly-derived mesenchymal stem cells from the umbilical cord for newly-onset type 1 diabetes mellitus. Endocr J 2013;60:347-357
30. Fischer UM, Harting MT, Jimenez F, et al. Pulmonary passage is a major obstacle for intravenous stem cell delivery: The pulmonary first-pass effect. Stem Cells Dev 2009;18:683-692
31. Lee RH, Seo MJ, Reger RL, et al. Multipotent stromal cells from human marrow home to and promote repair of pancreatic islets and renal glomeruli in diabetic NOD/scid mice. Proc Natl Acad Sci U S A 2006;103:17438-17443
32. Caballero S, Sengupta N, Afzal A, et al. Ischemic vascular damage can be repaired by healthy, but not diabetic, endothelial progenitor cells. Diabetes 2007;56:960-967
33. Fiorina P, Jurewicz M, Augello A, et al. Immunomodulatory function of bone marrowderived mesenchymal stem cells in experimental autoimmune type 1 diabetes. J Immunol 2009; 183:993-1004
34. Jurewicz M, Yang S, Augello A, et al. Congenic mesenchymal stem cell therapy reverses hyperglycemia in experimental type 1 diabetes. Diabetes 2010;59:3139-3147
35. Ianus A, Holz GG, Theise ND, Hussain MA. In vivo derivation of glucose-competent pancreatic endocrine cells from bone marrow without evidence of cell fusion. J Clin Invest 2003;111:843-850
36. Francese R, Fiorina P. Immunological and regenerative properties of cord blood stem cells. Clin Immunol 2010;136:309-322
37. Fiorina P, Voltarelli J, Zavazava N. Immunological applications of stem cells in type 1 diabetes. Endocr Rev 2011;32:725-754
38. Zhao M, Amiel SA, Ajami S, et al. Amelioration of streptozotocin-induced diabetes in mice with cells derived from human marrow stromal cells. PLoS One 2008;3:e2666
39. Miura M, Miura Y, Padilla-Nash HM, et al. Accumulated chromosomal instability in murine bone marrow mesenchymal stem cells leads to malignant transformation. Stem Cells 2006;24: 1095-1103
40. Tolar J, Nauta AJ, Osborn MJ, et al. Sarcoma derived from cultured mesenchymal stem cells. Stem Cells 2007;25:371-379